Cellectis S.A. (CLLS) is making notable progress in the field of allogeneic CAR-T cell therapies, with two key candidates, lasme-cel and eti-cel, showing promising results in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and B-cell non-Hodgkin lymphoma (r/r B-NHL) respectively. The company has maintained a 'Hold' rating as it continues to advance these innovative treatments through clinical trials, aiming to address critical unmet needs in cancer therapy.
Lasme-cel, designed for r/r B-ALL patients, has demonstrated a 100% overall response rate (ORR) in its phase 2 clinical trials. This exceptional outcome positions the therapy as a potential breakthrough for a patient population with limited options. The company anticipates releasing interim data from the pivotal phase 2 study in the fourth quarter of 2026, a critical milestone that could further validate its efficacy and safety profile.
Simultaneously, eti-cel, a unique dual-targeting CAR-T therapy against CD20 and CD22, is progressing in trials for heavily pretreated r/r B-NHL patients. Early data from phase 1 trials indicate an 88% ORR and a 63% complete remission (CR) rate, suggesting significant therapeutic potential. Full phase 1 data for eti-cel are also expected by the fourth quarter of 2026, offering more comprehensive insights into its performance.
From a financial perspective, Cellectis reports a cash runway that extends into the fourth quarter of 2027. However, to ensure sustained operations and further development beyond this period, the company will likely need to secure additional financing or forge strategic partnerships by early 2027. These financial considerations are integral to supporting the continued advancement of its therapeutic pipeline.
Cellectis is at the forefront of developing next-generation allogeneic CAR-T therapies, offering new hope for patients battling challenging blood cancers. The positive early clinical outcomes of lasme-cel and eti-cel underscore the potential of these treatments. The upcoming data readouts in late 2026 will be crucial in shaping the future trajectory of these therapies and the company's strategic financial planning.
